Salcedo A, Mayor F, Penela P (2006) Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J 25, 4752-62 17006543

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K19-ub - GRK2 (human) ▲

Modsite: SyLMAMEkSkATPAA SwissProt Entrez-Gene Orthologous residues GRK2 (human): K19‑ub, GRK2 (mouse): K19‑ub, GRK2 (rat): K19‑ub, GRK2 (cow): K19‑ub Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ARRB2 (human) increase isoproterenol increase siRNA decrease siRNA for Mdm2 decreases ubiquitination Downstream Regulation Effect of modification (function):  protein degradation

K21-ub - GRK2 (human) ▲

Modsite: LMAMEkSkATPAARA SwissProt Entrez-Gene Orthologous residues GRK2 (human): K21‑ub, GRK2 (mouse): K21‑ub, GRK2 (rat): K21‑ub, GRK2 (cow): K21‑ub Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ARRB2 (human) increase isoproterenol increase siRNA decrease siRNA for Mdm2 decreases ubiquitination Downstream Regulation Effect of modification (function):  protein degradation

K30-ub - GRK2 (human) ▲

Modsite: TPAARAskkILLPEP SwissProt Entrez-Gene Orthologous residues GRK2 (human): K30‑ub, GRK2 (mouse): K30‑ub, GRK2 (rat): K30‑ub, GRK2 (cow): K30‑ub Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ARRB2 (human) increase isoproterenol increase siRNA decrease siRNA for Mdm2 decreases ubiquitination Downstream Regulation Effect of modification (function):  protein degradation

K31-ub - GRK2 (human) ▲

Modsite: PAARAskkILLPEPS SwissProt Entrez-Gene Orthologous residues GRK2 (human): K31‑ub, GRK2 (mouse): K31‑ub, GRK2 (rat): K31‑ub, GRK2 (cow): K31‑ub Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  breast cancer, breast adenocarcinoma, breast cancer, triple negative Relevant cell lines - cell types - tissues:  293 (epithelial), MCF-7 (breast cell), MCF10A1 (epithelial), MDA-MB-468 (breast cell), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE MDM2 (human) siRNA inhibition of enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic knockout/knockin of upstream enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ARRB2 (human) increase isoproterenol increase siRNA decrease siRNA for Mdm2 decreases ubiquitination Downstream Regulation Effect of modification (function):  protein degradation